CY1113550T1 - Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης - Google Patents

Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Info

Publication number
CY1113550T1
CY1113550T1 CY20131100058T CY131100058T CY1113550T1 CY 1113550 T1 CY1113550 T1 CY 1113550T1 CY 20131100058 T CY20131100058 T CY 20131100058T CY 131100058 T CY131100058 T CY 131100058T CY 1113550 T1 CY1113550 T1 CY 1113550T1
Authority
CY
Cyprus
Prior art keywords
holoperidon
isomeri
variable
optical
fouoro
Prior art date
Application number
CY20131100058T
Other languages
English (en)
Inventor
Dominique Grimler
Hans O Kalkman
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1113550T1 publication Critical patent/CY1113550T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Φαρμακευτικές συνθέσεις και ιατρικές χρήσεις που περιλαμβάνουν είτε (R)-1-(4-{3-[4-(6-φθορο-βενζο(d)ισοξαζολ-3-υλ)-πιπεριδιν-1-υλ}-προποξυ}-3-μεθοξυ-φαινυλ)αιθανόλη του τύπου I:
CY20131100058T 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης CY1113550T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
EP10009915A EP2305656B1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
CY1113550T1 true CY1113550T1 (el) 2016-06-22

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111101053T CY1112039T1 (el) 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111101053T CY1112039T1 (el) 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Country Status (10)

Country Link
US (4) US20050020632A1 (el)
EP (2) EP1425272B1 (el)
JP (6) JP2005504783A (el)
AT (1) ATE518845T1 (el)
CY (2) CY1112039T1 (el)
DK (2) DK2305656T3 (el)
ES (2) ES2398434T3 (el)
HK (2) HK1066536A1 (el)
PT (2) PT2305656E (el)
WO (1) WO2003020707A1 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238780D1 (de) 2001-10-30 2011-02-10 Novartis Ag Depot formulierungen von iloperidone und einem sternförmigen polymer
IL164108A0 (en) 2002-03-27 2005-12-18 Glaxo Group Ltd Quinoline derivatives and their useas 5-ht6 ligands
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ES2825949T3 (es) 2004-09-30 2021-05-17 Vanda Pharmaceuticals Inc Métodos para administrar iloperidona
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
JP2009538331A (ja) * 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
EP2134873B1 (en) 2007-03-29 2015-05-06 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
WO2008144599A2 (en) 2007-05-18 2008-11-27 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
MX2010006521A (es) 2007-12-13 2010-08-10 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.
US8729100B2 (en) 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
EP2416778B1 (en) 2009-04-06 2016-03-02 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
JP5692872B2 (ja) 2009-04-06 2015-04-01 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｂａｉ遺伝子の配列又はその産物に基づいてｑｔ延長に対する素因を予測する方法
JP5800798B2 (ja) 2009-04-06 2015-10-28 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｋｃｎｑ１遺伝子の多型に基づいた治療方法
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
JP2015510893A (ja) * 2012-03-14 2015-04-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
BR112017017608A2 (pt) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
US11773118B2 (en) 2019-02-21 2023-10-03 Obi Pharma, Inc. Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
DE69021645T2 (de) 1989-05-19 1996-02-22 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
CA2296104A1 (en) * 1997-07-03 1999-01-14 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
PT2305656E (pt) 2013-01-10
EP1425272B1 (en) 2011-08-03
ATE518845T1 (de) 2011-08-15
US20110201646A1 (en) 2011-08-18
ES2370634T3 (es) 2011-12-21
EP1425272A1 (en) 2004-06-09
CY1112039T1 (el) 2015-11-04
JP2013227335A (ja) 2013-11-07
DK1425272T3 (da) 2011-11-21
US7977356B2 (en) 2011-07-12
ES2398434T3 (es) 2013-03-19
JP2015214577A (ja) 2015-12-03
JP2005504783A (ja) 2005-02-17
ES2398434T8 (es) 2017-10-09
JP2010100633A (ja) 2010-05-06
HK1156309A1 (en) 2012-09-07
JP2015227368A (ja) 2015-12-17
US20090176739A1 (en) 2009-07-09
EP2305656B1 (en) 2012-10-24
EP2305656A1 (en) 2011-04-06
US8314129B2 (en) 2012-11-20
HK1066536A1 (en) 2005-03-24
JP2013116905A (ja) 2013-06-13
DK2305656T3 (da) 2013-02-11
PT1425272E (pt) 2011-10-19
WO2003020707A1 (en) 2003-03-13
US20050020632A1 (en) 2005-01-27
US20130296366A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
CY1113550T1 (el) Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
ATE344033T1 (de) Vinylphenyl-derivate als glk-aktivatoren
NO20062370L (no) Amidderivater
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
ATE498600T1 (de) Inden derivate als pharmazeutika
DK1546119T3 (da) Fremgangsmåde til fremstilling af 4-(3'chlor-4'-fluoranilin)-7-methoxy-6-(3-morpholinpropoxy) quinazoline
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
HK1070363A1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
DE50005937D1 (de) 3-(4,5-dihydroisoxazol-5-yl)benzoylpyrazole
ATE389326T1 (de) 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazo e und ihre verwendung als herbizide
DK1384476T3 (da) Azolylcarbinolderivater af aryl (eller heteroaryl) til behandling af åndedrætssygdomme
DK1245564T3 (da) Benzamidinderivater
SE0102809D0 (sv) Novel compounds
RS52014B (sr) Nova so benzoilgvanidina
DE50014393D1 (de) Cyclopropyl-anellierte 3-(4,5-dihydroisoxazol-3-yl)-substituierte benzoylpyrazole als herbizide
ATE262521T1 (de) Pyrimidinyl methyl indolderivate mit antibakterieller wirkung
DE60115428D1 (de) Benzoesäureester mit antiplasmideffekt
DK1499312T3 (da) Anvendelse af hydroxypyridonderivater til sårheling
HUP0203536A2 (hu) 3-(4,5-Dihidroizoxazol-3-il)-szubsztituált benzoil-pirazolok
DE60211018D1 (de) Fungizide thiazolderivate